Patents by Inventor Atze Jacobus BERGSMA

Atze Jacobus BERGSMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotides useful in treatment of Pompe disease
    Patent number: 11859186
    Abstract: The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: January 2, 2024
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Atze Jacobus Bergsma, Erik Van Der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske Van Der Ploeg, Arnoldus Reuser
  • Enzymatic replacement therapy and antisense therapy for Pompe disease
    Patent number: 11286483
    Abstract: The invention relates to method for repairing aberrant; splicing, wherein such aberrant: splicing is caused by the presence of a natural pseudo exon, comprising blocking of either the natural cryptic 3? splice site or the natural cryptic 5? splice site of said natural pseudo exon with an antisense oligomeric compound (AON). Further, the invention comprises an antisense oligomeric compound targeting SEQ ID NO: 1 or SEQ ID NO: 171, preferably selected from the sequences of SEQ ID NO: 267-2040, sequences that are complementary to said sequences or sequences that have an identity of 80% with said sequences or the complementary sequences. The invention further envisages the use of two antisense oligomeric compounds, a first AON targeting SEQ ID NO: 1 and a second targeting AON or SEQ ID NO: 171. These AONs are specifically for use in the treatment of Pompe disease. It is an aspect of the invention that antisense therapy using the above AONs or combinations thereof is used in combination with ERT.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 29, 2022
    Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
    Inventors: Erik Van Der Wal, Atze Jacobus Bergsma, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske Van Der Ploeg
  • ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE
    Publication number: 20210322526
    Abstract: The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene.
    Type: Application
    Filed: May 3, 2021
    Publication date: October 21, 2021
    Inventors: Erik van der Wal, Atze Jacobus Bergsma, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus Reuser
  • ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE
    Publication number: 20210139913
    Abstract: The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 13, 2021
    Inventors: Atze Jacobus BERGSMA, Erik Van Der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske Van Der Ploeg, Arnoldus Reuser
  • Enzymatic replacement therapy and antisense therapy for pompe disease
    Patent number: 10993995
    Abstract: The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: May 4, 2021
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Erik van der Wal, Atze Jacobus Bergsma, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus Reuser
  • Antisense oligonucleotides useful in treatment of Pompe disease
    Patent number: 10829764
    Abstract: The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: November 10, 2020
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Atze Jacobus Bergsma, Erik Van Der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske Van Der Ploeg, Arnoldus Reuser
  • Methods for characterizing alternatively or aberrantly spliced mRNA isoforms
    Patent number: 10724092
    Abstract: The disclosure provides method and kits for characterizing spliced m RNA isoforms. The disclosure also provides methods of screening for mutations and oligonucleotides that modulate splicing.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: July 28, 2020
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Atze Jacobus Bergsma, Erik van der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus Reuser
  • ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE
    Publication number: 20200138846
    Abstract: The invention relates to method for repairing aberrant; splicing, wherein such aberrant: splicing is caused by the presence of a natural pseudo exon, comprising blocking of either the natural cryptic 3? splice site or the natural cryptic 5? splice site of said natural pseudo exon with an antisense oligomeric compound (AON). Further, the invention comprises an antisense oligomeric compound targeting SEQ ID NO: 1 or SEQ ID NO: 171, preferably selected from the sequences of SEQ ID NO: 267-2040, sequences that are complementary to said sequences or sequences that have an identity of 80% with said sequences or the complementary sequences. The invention further envisages the use of two antisense oligomeric compounds, a first AON targeting SEQ ID NO: 1 and a second targeting AON or SEQ ID NO: 171. These AONs are specifically for use in the treatment of Pompe disease. It is an aspect of the invention that antisense therapy using the above AONs or combinations thereof is used in combination with ERT.
    Type: Application
    Filed: June 14, 2018
    Publication date: May 7, 2020
    Applicant: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
    Inventors: Erik VAN DER WAL, Atze Jacobus BERGSMA, Wilhelmus Wenceslaus Matthias PIJNAPPEL, Antje Tjitske VAN DER PLOEG
  • ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE
    Publication number: 20190241897
    Abstract: The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 8, 2019
    Inventors: Atze Jacobus Bergsma, Erik Van Der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske Van Der Ploeg, Arnoldus Reuser
  • Antisense oligonucleotides useful in treatment of Pompe disease
    Patent number: 10308940
    Abstract: The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 4, 2019
    Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
    Inventors: Atze Jacobus Bergsma, Erik van der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus Reuser
  • ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE
    Publication number: 20180360927
    Abstract: The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene.
    Type: Application
    Filed: December 7, 2015
    Publication date: December 20, 2018
    Inventors: Erik van der Wal, Atze Jacobus Bergsma, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus Reuser
  • METHODS FOR CHARACTERIZING ALTERNATIVELY OR ABERRANTLY SPLICED MRNA ISOFORMS
    Publication number: 20170306399
    Abstract: The disclosure provides method and kits for characterizing spliced m RNA isoforms. The disclosure also provides methods of screening for mutations and oligonucleotides that modulate splicing.
    Type: Application
    Filed: June 10, 2015
    Publication date: October 26, 2017
    Inventors: Atze Jacobus BERGSMA, Erik van der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus REUSER
  • ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE
    Publication number: 20170247704
    Abstract: The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.
    Type: Application
    Filed: June 10, 2015
    Publication date: August 31, 2017
    Inventors: Atze Jacobus BERGSMA, Erik van der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus REUSER